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Abstract The mycobacterial Rv1625c gene product is an ade-
nylyl cyclase with sequence similarity to the mammalian en-
zymes. The catalytic domain of the enzyme forms a homodimer
and residues specifying adenosine triphosphate (ATP) speci¢city
lie at the dimer interface. Mutation of these residues to those
present in guanylyl cyclases failed to convert the enzyme to a
guanylyl cyclase, but dramatically reduced its adenylyl cyclase
activity and altered its oligomeric state. Computational model-
ing revealed subtle di¡erences in the dimer interface that could
explain the biochemical data, suggesting that the structural and
catalytic features of this homodimeric adenylyl cyclase are in
contrast to those of the heterodimeric mammalian enzymes.
* 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The mammalian adenylyl cyclases that are regulated by the
heterotrimeric G-proteins are large polypeptides containing 12
transmembrane spanning helices with two catalytic domains,
C1 and C2. The catalytic domains of the mammalian enzymes
have been characterized extensively both biochemically and
structurally, and are active as heterodimers of the C1 and
the C2 polypeptide regions, forming a single catalytic site at
the interface [1]. This appears to be in contrast to the type III
cyclases present in genomes from other organisms. The ge-
nome of Mycobacterium tuberculosis H37Rv, a parasite resid-
ing in host alveolar macrophages, contains 16 open reading
frames that code for putative class III nucleotide cyclase genes
[2,3]. Some of the mycobacterial genes bear a high degree of
sequence similarity to mammalian adenylyl and guanylyl cy-
clases, and two of these genes, Rv1264 and Rv1625c, have
been shown to have adenylyl cyclase activity [4^6] and func-
tion as homodimers.
The substrate selectivity of the type III nucleotide cyclases
has been studied by mutational analysis and structure-based
modeling, and residues that select for adenosine triphosphate
(ATP) or guanosine triphosphate (GTP) have been identi¢ed
[7]. Adenylyl cyclases have lysine (Lys-938 in type II C2) and
aspartate (Asp-1018 in type II C2) residues in the catalytic
cleft, which are replaced by glutamate and cysteine residues
in guanylyl cyclases (Glu-925 and Cys-997 in retinal guanylyl
cyclase). Switching of residues in a soluble [8] and membrane-
bound guanylyl cyclase [9] to those in adenylyl cyclases led to
the conversion of the guanylyl cyclases to adenylyl cyclases,
but a similar exchange of residues in an adenylyl cyclase gave
rise to a non-speci¢c purine cyclase [8]. Substrate selectivity of
cyclases from unicellular organisms has also been altered by
similar mutations [10^12]. The active site of the mammalian
enzymes lies at the dimer interface and the crystal structures
of the inactive C2 homodimer and the C1-C2 heterodimer
reveal a rotation of the C1 domain relative to C2 that opti-
mizes substrate conversion [1]. However the role of substrate-
specifying residues in the positioning of the two subunits, if at
all, has not been studied.
The Rv1625c gene product comprises a protein with six
transmembrane helices and a single cytosolic catalytic do-
main, which dimerizes to form a 12-transmembrane, homodi-
meric enzyme, with two catalytic centers, in contrast to the
heterodimeric mammalian enzyme [6]. It therefore provides an
opportunity to study biochemical and structural features that
could be distinct from the mammalian enzymes. Based on the
ability of the heterodimeric mammalian enzymes to convert
their nucleotide speci¢city by mutational analysis, we decided
to investigate the role that these residues present at the dimer
interface play in Rv1625c to compare and contrast its proper-
ties with its mammalian counterparts. We show here, by bio-
chemical analysis and computational modeling approaches,
that residues that specify the substrate in mammalian nucleo-
tide cyclases can alter the dimer-forming ability and interface
of the Rv1625c cyclase. Our studies therefore suggest a new
role for these residues in regulating the catalytic activity of
homodimeric nucleotide cyclases, in their ability to subtly al-
ter the dimeric interface of these enzymes.
2. Materials and methods
2.1. Bioinformatics
The Rv1625c sequence was aligned with representative members of
the adenylyl and guanylyl cyclases and multiple sequence alignments
were performed using Clustal X [13]. The amino acid sequences of the
catalytic domains of several class III nucleotide cyclases were obtained
from the Simple Modular Architecture Research Tool (SMART) da-
tabase [14,15] (http://smart.embl-heidelberg.de/). The catalytic domain
of class III nucleotide cyclases has a SMART accession number
SM0044 (CycC).
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A three-dimensional model for the catalytic domain of Rv1625c
was generated on the basis of the available crystal structures of rat
type II C2 homodimeric adenylyl cyclase (Code: 1ab8), and C1 and
C2 adenylyl cyclase subunits bound to GsK (Code: 1azs). Simulta-
neous use of the three tertiary structures has been made in the mod-
eling of Rv1625c using the COMPOSOR suite of programs [16^18]
encoded in the SYBYL software (Tripos Inc., St. Louis, MO,
USA). The dimeric model of Rv1625c has been generated on the basis
of the dimeric crystal structures. The structural model has been energy
minimized using the AMBER force-¢eld [19]. SETOR program was
used to view the structures and draw Fig. 4 [20].
2.2. Cloning, expression and puri¢cation of Rv1625c gene product
Primers (626f, 5P-AGGCGGCCATGGAGGCGGAGCAC-3P and
1355r, 5P-GGCCCCGGGATAAAGCTTGGCGG-3P) were designed
to the catalytic domain of Rv1625c, corresponding to amino acids
212^443 as per annotation at The Institute for Genomic Research
(TIGR) website http://www.tigr.org, and based on multiple sequence
alignment of several adenylyl and guanylyl cyclases. The product ob-
tained from the polymerase chain reaction (PCR) using the cosmid
MTCY0IB2 (Cole, S.T., Institute Pasteur, France) as template (10 ng),
was cloned in the pCRII vector (Invitrogen) to generate the plasmid
pCRII-Rv1625c212443 and the cloned insert sequenced. The insert was
then cloned into pRSET-B vector (Invitrogen), using the NcoI^Hin-
dIII sites in the primers, to generate plasmid pRSET-Rv1625c212443,
and the C43(DE3) derivative of Escherichia coli BL21(DE3) [21] was
used for production of protein. The protein synthesized has an
N-terminal hexa-histidine tag and was puri¢ed using Ni-NTA agarose
(Qiagen). Puri¢ed protein was stored in 20 mM HEPES^NaOH bu¡er
(pH 7.5) and 2 mM 2-mercaptoethanol (2-ME) containing 10% glyc-
erol at 370‡C until use. Enzyme remained active for months under
these conditions. Protein estimation was performed by the method of
Bradford with modi¢cations [22]. An antibody was raised to the cata-
lytic domain fused to glutathione S-transferase (data not shown),
a⁄nity puri¢ed against the catalytic domain protein and used for
Western blot analysis.
2.3. Gel ¢ltration analysis and cross-linking
Gel ¢ltration was performed in 20 mM HEPES^NaOH bu¡er (pH
7.5), 5 mM 2-ME and 10% glycerol on an AKTA fast protein liquid
chromatography (FPLC) system using a Superdex 200 column (25
cmU1 cm, Amersham Pharmacia Biotech) at a £ow rate of 0.2 ml
min31. The column was calibrated with bovine thyroglobin (669
kDa), IgG (150 kDa), serum albumin (66 kDa), ovalbumin (45
kDa) and cytochrome c (12.3 kDa).
Cross-linking was performed using 1 Wg of puri¢ed protein in 50
mM HEPES^NaOH bu¡er, pH 7.5, 1 mM dithiothreitol (DTT) and
10% glycerol in the presence of 2 mM disuccinimidyl suberate (DSS)
or an equivalent amount of the solvent, dimethyl sulfoxide. The re-
action was allowed to proceed for 30 min at room temperature and
was terminated by addition of 4U Laemmli loading dye. Samples
were subjected to sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE), followed by Western blotting using an a⁄n-
ity-puri¢ed antibody to the Rv1625c catalytic domain. Immunoreac-
tive bands were visualized by enhanced chemiluminescence as
described earlier [23].
2.4. Adenylyl and guanylyl cyclase assays
Adenylyl cyclase assay tubes were incubated at 25‡C in a total
volume of 50 Wl, in 50 mM HEPES^NaOH bu¡er (pH 7.5), 1 mM
DTT and 10% glycerol, for 10 min. Protein concentration used was
600 nM, and these conditions were found to allow linearity of product
formation under the conditions of the assay. MnATP concentrations
were varied up to a maximum of 2 mM and the free Mn concentra-
tions in excess of the amount required for formation of metal-ATP,
was kept at 10 mM. The concentrations of free metals and metal-ATP
complexes in assays were calculated using WinmaxC (http://
www.stanford.edu/Vcpatton/maxc.html [24]). Guanylyl cyclase assays
were carried out for 10 min at 37‡C in the presence of 1 mM GTP and
10 mM MnCl2, or 10 mM GTP and 50 mM MnCl2. Assays were
terminated by the addition of 50 mM sodium acetate bu¡er (pH
4.3) and boiling of the samples. Suitable volumes were used for cyclic
nucleotide estimation with modi¢cations [25]. The cAMP radioimmu-
noassay could detect 10 fmol of cAMP per tube. The cGMP assay
was performed only after acetylation of samples and could detect
1 fmol of cGMP per tube. Enzyme kinetics data were ¢tted to the
Michaelis^Menten equation or the Hill equation [26] using GraphPad
Prism (San Diego, CA, USA). Where mentioned, values represent
meanSS.E.M. from experiments performed at least thrice.
2.5. Mutagenesis of Rv1625c
Plasmids pCRII-Rv1625c212443 or pRSET-Rv1625c212443 were
used for site-directed mutagenesis of the catalytic domain. The ¢rst
primer mutated a lysine (Lys-296) to an aspartate residue and had the
sequence 5P-TGGAGAAAATCGAGGTCAGCGGGGA-3P (primer
KE). The second primer, DC, had the sequence 5P-TCGCCCCA-
CACGCAGTAGAAGAACCG-3P and mutated an aspartate (Asp-
365) to a cysteine residue. The two products generated using primer
KE and primer 1355r, and primer DC and primer 626f, were taken for
overlap PCR at 68‡C for 10 cycles. An aliquot of this PCR was re-
ampli¢ed with primers 626f and 1355r and the product was cloned in
to pCRII vector (Invitrogen) to generate the plasmid pCRII-Rv1625c-
KCE. Sequencing showed the presence of only the K296E mutation,
though both mutations were expected. The D365C mutant was ob-
tained by a modi¢cation of the DpnI digestion method of mutagenesis
[27]. pCRII-Rv1625c-KCE was used as a template and sequencing
con¢rmed the presence of the additional D365C mutation and this
plasmid was called pCRII-Rv1625c-KDCEC. Both these mutants
were subcloned into the pRSET-B vector at the NcoI^HindIII sites
(Invitrogen) to generate pRSET-KE and pRSET-KDEC. The D365C
single mutant was obtained by ligating an NcoI^SacII fragment from
pCRII-Rv1625c212443 and a SacII^HindIII fragment from pCRII-
Rv1625c-KDCEC to generate pRSET-DC. The F363R mutation
was generated by similar DpnI-based mutagenesis on the pRSET-
KDEC plasmid using the FR primer 5P-TCGACGGTTCCGC-
TACTGCGTGTGGG-3P to generate plasmid pRSET-KFDCERC.
The mutant proteins are referred to as KCE, DCC, KDCEC and
KFDCERC throughout the text. All mutants have been sequenced
to rule out the presence of other missense mutations. Proteins were
expressed in the E. coli C43(DE3) strain and puri¢ed using procedures
adopted for the wild-type protein. Cross-linking and gel ¢ltration
analysis were performed as described above for the wild-type protein.
3. Results and discussion
3.1. Expression and puri¢cation of the catalytic domain of
Rv1625c
The catalytic domain of Rv1625c has been shown to aggre-
gate at high protein concentrations, thereby reducing its cata-
lytic activity [6]. We therefore expressed a region of the pro-
tein that is more closely de¢ned at its N-terminus by residues
that show similarity to other adenylyl and guanylyl cyclases
(Fig. 1). Also shown in Fig. 1 are residues that confer nucle-
otide speci¢city in adenylyl and guanylyl cyclases, and as can
be seen, the catalytic domain of Rv1625c shows similarity to
both adenylyl and guanylyl cyclases in regions around the
substrate-specifying residues identi¢ed by computational anal-
ysis of cyclase sequences [28].
The expressed protein was puri¢ed (Fig. 2A) and adenylyl
cyclase assays were performed in the presence of Mn as metal
cofactor. The activity showed a sigmoidal substrate response
curve (Fig. 2B), indicating that the two catalytic centers in the
enzyme interact with each other, in contrast to the classical
hyperbolic catalysis seen with the puri¢ed C1 and C2 domains
of the mammalian adenylyl cyclase, which form a single cata-
lytic center [29]. The Hill coe⁄cient calculated from the data
was 3.9S 0.6 and the apparent KPMnATP was 363S 43 WM,
indicating a highly cooperative interaction between the two
substrate binding regions in the protein.
The expressed protein was subjected to gel ¢ltration analy-
sis and, as shown in Fig. 2C, eluted largely as a monomeric
species with some amount of dimer. Cross-linking of the pro-
tein with DSS was in agreement with these observations (Fig.
2C). Cross-linking was also observed in the presence of
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MnATP (data not shown), but no cross-linked product was
observed with disuccinimidyl tartarate, indicating that cross-
linking was speci¢c and depended on the correct positioning
of lysine residues in the protein (data not shown). The fact
that this protein was less prone to aggregation at high con-
centrations, in contrast to an earlier described catalytic do-
main construct [6], allowed us to study residues that confer
substrate selectivity and are required for maintaining the olig-
omeric status of the enzyme as described below.
3.2. Residues that confer nucleotide selectivity also are involved
in productive dimer formation
The crystal structure of the C1-C2 domains of the mamma-
lian enzyme revealed that a main chain carbonyl interacts with
the adenine N6 and helps in contributing to the speci¢city of
nucleotide binding, along with the substrate-specifying resi-
dues, lysine and aspartate [30]. Therefore, mutation of the
lysine and aspartate residues in adenylyl cyclases to a gluta-
mate and a cysteine present in guanylyl cyclases converts these
enzymes to a non-speci¢c cyclase [8], but increases the Km for
ATP dramatically. Given the signi¢cant sequence similarity of
Rv1625c with both adenylyl and guanylyl cyclases, we wished
to evaluate the importance of the substrate-specifying residues
(Lys-296 and Asp-365) in Rv1625c, by mutational analysis, in
an attempt to convert it to a guanylyl cyclase.
Wild-type Rv1625c showed no guanylyl cyclase activity us-
ing as much as 10 mM GTP as substrate [6] (data not shown).
We generated four mutant proteins, K296E and D365C with
single mutations in residues that interact with either ATP or
GTP in adenylyl and guanylyl cyclases respectively, and
K296E/D365C with both mutations (Fig. 1). In addition, a
third mutation shown to be required for e⁄cient conversion
of an adenylyl cyclase to a guanylyl cyclase [7,8] was also
generated and involved the mutation of a phenylalanine resi-
due to an arginine residue (K296E/F363R/D365C triple mu-
tant). All mutant proteins were puri¢ed and tested for cata-
lytic activity. Interestingly, none of the mutant proteins
demonstrated any guanylyl cyclase activity, though the assay
using radioiodinated cGMP that we use is capable of detect-
ing fmol concentrations of cGMP per tube [23]. Even concen-
trations of GTP as high as 10 mM failed to show any for-
mation of cGMP (data not shown).
However, all proteins demonstrated some adenylyl cyclase
activity, but much lower than that of the wild-type enzyme.
Moreover, mutant proteins displayed classical Michaelis^
Menten kinetics, as opposed to the sigmoidal nature of the
wild-type enzyme (Fig. 3A), indicating that the communica-
tion between the two catalytic sites was lost, perhaps as a
consequence of altered positioning of the two subunits in
the region of the catalytic center. The a⁄nity of the enzymes
for MnATP did not di¡er dramatically, but the Vmax, and, as
a consequence, the speci¢c activities of the mutant proteins,
was markedly compromised, as compared to the wild-type
enzyme.
Fig. 1. Sequence analysis of the Rv1625c catalytic domain. Class III nucleotide cyclase catalytic domain amino acid sequences were obtained
from the SMART database and multiply aligned using Clustal X. Residues specifying the nucleotide demonstrated biochemically are highlighted
in black, and those additionally identi¢ed through sequence analysis are highlighted in gray [28]. C. fam: Canis familiaris ; R. nor: Rattus nor-
vegicus ; H. sap: Homo sapiens ; M. mus: Mus musculus ; M. sex: Manduca sexta ; M. tub: M. tuberculosis. The proteins used for the alignment
are as follows ACV-C1:P30803; ACII-C2:P26769; sAC:Q96PN6; sGC-a1:Q9ERL9; sGC-b3:O76340; ret-GC-2:P51841; and Rv1625c:O30820.
Notice the similarity of the Rv1625c to both adenylyl and guanylyl cyclases.
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The low adenylyl cyclase activity of the mutant proteins
was not because of general misfolding as seen from their gel
¢ltration pro¢les (see below) where they eluted with well-de-
¢ned hydrodynamic parameters. In addition, we did not ob-
serve any change in the expression levels or the solubility of
the wild-type and mutants proteins, again indicating that mu-
tations had not compromised the folding in E. coli cells. We
therefore decided to check if the loss of activity was due to
inability of the mutants to form functional dimers.
Cross-linking and gel ¢ltration analysis were performed
with the wild-type and mutant proteins (Fig. 3B). Cross-link-
ing experiments (Fig. 3B, insets) showed that KDCEC and
DCC mutants could cross-link to form dimers in the pres-
ence of DSS, indicating that K296 may not be directly in-
volved in forming cross-links. No dimers were seen with the
KCE mutant under similar conditions, but overexposure of
the Western blot did show a small amount of dimer (data not
shown). Gel ¢ltration analysis demonstrated a di¡erence in
the oligomeric states of the mutant proteins (Fig. 3) in agree-
ment with the cross-linking results. The gel ¢ltration pro¢le of
the KCE mutant was similar to that of the wild-type enzyme
(Fig. 3), showing the presence of a signi¢cant amount of
monomeric protein species. In contrast, the KDCEC double
mutant and DCC single mutant contain large amounts of the
dimer, with very little monomeric species. This dimerization
was not due to the formation of a disul¢de bridge between the
two single cysteine residues present in the mutant proteins,
since puri¢ed proteins were always stored in reducing agent
(see Section 2). The triple mutant, KFDCERC was found to
exist predominantly as a monomer and showed very little
Fig. 2. Catalytic activity and dimeric nature of the catalytic domain of Rv1625c. A: The catalytic domain (5 Wg) of Rv1625c was puri¢ed sub-
jected to SDS^gel electrophoresis and stained with Coomassie. B: Adenylyl cyclase assays were performed in the presence of a ¢xed concentra-
tion of 10 mM free Mn and varying concentrations of MnATP as indicated. Values shown are representatives of assays performed at least
thrice. C: Gel ¢ltration analysis of the puri¢ed Rv1625c catalytic domain protein was performed on a Superdex 200 column. Protein eluting at
positions corresponding to a monomer and a dimer are shown. Inset: Cross-linking of the puri¢ed catalytic domain of Rv1625c was performed
with DSS and subjected to SDS^PAGE and Western blot analysis with an a⁄nity-puri¢ed antibody to the catalytic domain of Rv1625c.
FEBS 27367 4-6-03 Cyaan Magenta Geel Zwart
A.R. Shenoy et al./FEBS Letters 545 (2003) 253^259256
Fig. 3. Catalytic activity and gel ¢ltration analysis of mutant Rv1625c proteins. A: Puri¢ed proteins (2 Wg) were used for adenylyl cyclase as-
says using varying concentrations of MnATP as substrate in the presence of a ¢xed concentration of 10 mM Mn. Data shown are representa-
tives of assays performed thrice. B: Puri¢ed proteins (75^100 Wg) were subjected to gel ¢ltration analysis. The KCE and KFDCERC mutant
proteins existed predominantly as monomers, while the DCC and KDCEC mutant proteins had more of the dimeric species. Proteins corre-
sponding to monomer (30 kDa) and dimer (60 kDa) are seen. Insets: Puri¢ed mutant proteins (1 Wg each) were treated with dimethyl sulfoxide
(lanes marked 3) or cross-linked with DSS (lanes marked +) and subjected to Western blot analysis using an a⁄nity-puri¢ed antibody to
Rv1625c.
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dimer formation on cross-linking. These results therefore sug-
gest that mutation of the substrate-specifying residues, present
at the dimer interface of Rv1625c, also regulate the extent of
dimer formation, and suggest an additional role for these
residues in forming a productive catalytic cleft between the
two monomers of the enzyme, that can allow correct binding
of ATP and allow conversion to cAMP.
3.3. Computational modeling of the Rv1625c catalytic domain
In order to put these observations in a structural context,
we modeled the homodimeric catalytic domain of Rv1625c,
using information from available crystal structures [30,31]. As
the sequence identity between the cyclase domains of Rv1625c
and known structures of adenylyl cyclases was su⁄ciently
high (32^36%; [16]), most of the regions could be modeled
reliably. Fig. 4A shows the overall fold of the dimeric model
of Rv1625c. Structural regions with contiguous non-conserva-
tive substitutions in amino acid sequence compared to cy-
clases of known structure are highlighted in red. Most of
the regions that show maximum deviation are solvent-exposed
loops and terminus regions of helices and L-strands. The last
30 residues of Rv1625c show no high similarity with the cor-
responding regions of cyclases of known structure, and this
region is hypervariable even amongst the cyclases of known
structure.
The critical residues responsible for providing substrate se-
lectivity, Lys-296 and Asp-365, were modeled in the confor-
mations similar to that seen in the crystal structures (Fig. 4B).
Hence, they appear to be involved in an intra-chain salt bridge
formation, and are involved in stabilization of the tertiary
structure of each subunit. When the lysine or aspartate resi-
dues in Rv1625c are mutated to equivalent residues in gua-
nylyl cyclases (glutamate or cysteine), favorable intra-subunit
interactions between these two residues would be lost, possi-
bly leading to instability of the tertiary structure of the indi-
vidual polypeptide chains, thereby reducing catalytic activity
and altering dimer formation and positioning of the two sub-
units as we have observed experimentally.
While many of the putative interfacial residues in Rv1625c
are conserved with respect to the crystal structures of the
mammalian enzymes, there are some di¡erences. Most signi¢-
cantly, phenylalanine at position 363 is present in the interface
region. The equivalent residue in most of the adenylyl cyclases
is glutamine and that in guanylyl cyclases is arginine (Fig. 1).
Thus, the loss of Phe-363 in the KFDCERC mutant protein
could abolish the stacking interaction between the aromatic
rings of Phe-363 from the two subunits. Moreover, the intro-
duction of the charged residue arginine could further disable
homodimer formation, as is evident from the predominantly
monomeric nature of the triple mutant protein.
In spite of the higher overall sequence similarity to guanylyl
cyclases, GTP could not be used as a substrate by Rv1625c,
after replacement of ATP-specifying residues to those at
equivalent positions in guanylyl cyclases. The fact that ade-
nylyl cyclases with a single catalytic site showed some guanyl-
yl cyclase activity by similar mutations, indicates that sub-
strate-specifying residues in Rv1625c play an additional role
in its quaternary structure, distinct from that in mammalian
enzymes. Substrate speci¢city change in the homodimeric ret-
inal receptor guanylyl cyclase could take place with only two
mutations [9], while the heterodimeric soluble guanylyl cyclase
required three mutations [8]. Interestingly, mutation of this
third residue (Phe-363) to arginine in Rv1625c, which stabil-
izes the glutamate residue in mammalian guanylyl cyclases,
was found to be detrimental to dimerization as seen in gel
¢ltration experiments and as predicted by homology modeling
(Figs. 3 and 4). This again suggests subtle structural di¡er-
ences between the single catalytic centered mammalian ade-
nylyl and soluble guanylyl cyclases and the double catalytic
centered receptor guanylyl cyclases and Rv1625c, and points
to the uniqueness of the Rv1625c substrate binding pocket.
Fig. 4. Three-dimensional model of dimeric Rv1625c. A: Ribbon
representation of the model of Rv1625c generated on the basis of
the known related structures. The structural regions with deviation,
in terms of local sequence similarity with the cyclases of known
structure, are shown in red. B: Close-up of the inter-protomer inter-
face of the three-dimensional model of dimeric Rv1625c. The C-al-
pha traces of the two subunits are shown in brown and green re-
spectively. Phe-363 and the catalytic residues Lys-296 and Asp-365
from the two subunits are shown. The predicted salt bridge between
these residues and an interaction between the aromatic groups of
the side chains of Phe-363 residues from the two subunits are repre-
sented by dotted spheres. The ¢gure was generated using SETOR
[20].
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We did not expect residues involved in ATP binding to
regulate the oligomeric status of the protein despite the fact
that they lie at the dimer interface. The high cooperativity
observed with MnATP in the wild-type enzyme, however, in-
dicates that the protein undergoes a signi¢cant conformation-
al change upon binding the ¢rst molecule of MnATP. The
single mutation of KCE abolished the cooperativity of the
enzyme with respect to ATP binding, and also reduced cata-
lytic activity by almost 200-fold. More dramatic reductions in
catalytic activity were seen with the additional mutant pro-
teins. Given the somewhat smaller change in the apparent Km
for ATP, it is likely that the accurate juxtaposing of catalytic
residues brought about after binding of substrate is lacking in
the mutants, that leads to a reduced activity, rather than a
reduced binding of substrate. This clearly implies a greater
role for substrate-specifying residues in Rv1625c than has
been observed in the mammalian enzymes.
The presence of excess GTP in the reaction did not inhibit
the adenylyl cyclase activities of either the wild-type or the
mutant proteins, nor was guanylyl cyclase activity seen even
with high (10 mM) concentrations of GTP. Therefore,
Rv1625c and the mutant proteins are unable to bind GTP,
and utilize it as a substrate. Additional residues suggested to
provide substrate speci¢city have been identi¢ed, and muta-
tions of these residues (indicated in Fig. 1; [28]) could perhaps
alter substrate speci¢city in Rv1625c. Indeed, the requirement
of K and D for optimal positioning of catalytic residues in
Rv1625c raises the question as to whether this enzyme can be
converted to a guanylyl cyclase without altering the K and E
residues, and by mutating other residues, as described by
Hannenhalli and Russell [28]. The catalytic site of nucleotide
cyclases is formed at the dimer interface and therefore it is
attractive to suggest that additional residues required for ca-
talysis may also regulate dimer formation and structure of
Rv1625c. These could include residues that interact with the
metal ions essential for catalysis, and given the apparent dif-
ference in the dimer interface of Rv1625c, it is possible that
regulation of this enzyme by metals may di¡er from the mam-
malian enzymes as well. Such studies are currently ongoing in
the laboratory.
Rv1625c is one of the many putative genes in the genome of
M. tuberculosis H37Rv that has a high sequence similarity to
the class III nucleotide cyclases. As we have shown here,
despite the high (V60% similarity to guanylyl cyclases) se-
quence similarity to the mammalian enzymes, Rv1625c has
unique properties that have not been reported in any other
class III cyclase so far. These di¡erences could in principle be
exploited to understand in greater detail the evolution and
structural features of the large family of nucleotide cyclases.
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